Update on on-label and off-label use of JAK inhibitors
Julien Seneschal is professor of dermatology at the University Hospital of Bordeaux, National Reference Center for Rare Skin disorders. After a post-doctoral fellowship at Harvard University, focusing his research on skin immunology, he created an immuno-dermatology team with the goal to better understand the immune pathogenesis of inflammatory skin disorders such as atopic dermatitis and vitiligo. He is authors of several clinical and research articles related to skin inflammatory diseases published in Journal of Investigative Dermatology, Science Translational Medicine and Immunity, among others. He is an EADV member, a board member of the European Society for Dermatological Research (ESDR) and the president of the French Society for Research in Dermatology.
Lecture summary: The discovery of Janus-Associated Kinase (JAK) and their roles in cytokine action represents a significant advance in the understanding in cell signaling. Since many cytokines are involved in the immune mechanisms of chronic inflammatory skin disorders, the strategy of targeting JAKs in order to treat skin diseases is now a reality. Several oral and topical JAK inhibitors are currently under development for diseases such as atopic dermatitis, psoriasis, vitiligo, alopecia areata and hidradenitis suppurativa. In addition, many other skin inflammatory diseases with high unmet needs could benefit from these drugs. However, since they are a relatively new treatment modality in dermatology, their safety still needs to be confirmed.
This talk will explore the mechanism of action of JAK inhibitors, on-label and off-label use of topical and systemic JAK inhibitors and, last but not least, the current knowledge on the efficacy and safety of JAK inhibitors in dermatology.
(Boston, United States)
Management of squamous cell carcinoma from in situ to metastatic
Chrys Schmults is an associate professor of dermatology at Harvard. She received her medical degree from Yale and did her residency at New York University. She was a part of the faculty at the University of Pennsylvania before becoming the director of the Brigham and Women’s Hospital Mohs and Dermatologic Surgery Center in Boston. She founded the Dana Farber High-Risk Skin Cancer Clinic that cares for patients with multiple skin cancers, severe sun damage, or tumors at high risk for recurrence.
Dr Schmults has developed new staging systems for SCC and BCC which identified the subset of patients in need of studies of staging and adjuvant treatment. She has served on the board of directors of the American College of Mohs Surgeons and the International Society for Dermatologic Surgery, and as president of the International Immunology and Transplant Skin Cancer Collaborative. She is currently the chair of the non-melanoma panel of the National Comprehensive Cancer Network (NCCN) which develops guidelines of care for cancer patients.
Dr. Schmults’ talk will provide information on how to design appropriate treatment strategies for patients with field cancerization/multiple actinic keratosis and in situ SCCs, how to produce accurate prognostic estimates based on available data for patients with multiple and high-risk SCC and how to design appropriate treatment and follow-up strategies for patients with high risk and advanced SCC.